Please assess the completion status of the following clinical trial:

Trial Title: Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of one of the following~  * Newly diagnosed de novo acute myeloid leukemia (AML)~ * AML secondary to myelodysplastic syndromes (MDS)~ * AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years~* Bone marrow blasts \>30%~* Age ≥ 65 years~* Easter Cooperative Oncology Group (ECOG) 0-2~Exclusion Criteria:~* Previous cytotoxic or biologic treatment for AML (except hydroxyurea)~* Previous treatment with azacitidine, decitabine or cytarabine~* Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors)~* AML French American British subtype (FAB M3)~* AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes~* Prior bone marrow or stem cell transplantation~* Candidate for allogeneic bone marrow or stem cell transplant~* Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, in-situ carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)~* Malignant hepatic tumors~* Uncontrolled systemic infection~* Active viral infection with Human Immunodeficiency Virus (HIV) or Hepatitis type B or C~* Use of any experimental drug or therapy within 28 days prior to Day 1

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
- Conventional Care Regimen (Type: ACTIVE_COMPARATOR): Conventional Care Regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).